מקדם חוב לטווח ארוך להון igcinc.us (IGC)

A stable R&D staff and expert loyalty support the development of IGC Pharma, Inc. (IGC), while the long-term debt-to-equity ratio has settled at 0.02. IGC Pharma, Inc. (IGC) is creating safe alternatives to psychotropic drugs to combat dementia by combining AI and cannabinoids. Revenue is based on the development of Alzheimer's treatments, as well as the sale of health products and infrastructure solutions.

The metric is calculated as the ratio of liabilities with a maturity of over one year to total equity, determining the extent to which long-term financing depends on shareholders' funds. This is critical for IGC Pharma, Inc. (IGC), as synthesis automation requires capital expenditures while clinical trials depend on human resources. By analyzing the long-term debt-to-equity trend, an investor assesses the sustainability of the company's financial leverage.